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Ivabradine -Corlanor (Amgen)
Comparative agents:
None
Indication:
Reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta blockers or have a contraindication to betablocker use
Mechanism of action:
Hyperpolarization-activated cyclic nucleotide-gated channel blocker • Using other agents known to affect cardiac conduction or contractility with diltiazem may increase the risk of bradycardia, AV block, and heart failure. Interactions with Cytochrome P-450 3A4 Substrates, Inhibitors and Inducers [section added]
• Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system. • Clinically significant adverse reactions, potentially leading to severe, lifethreatening, or fatal events from greater exposures of concomitant medications.
• Clinically significant adverse reactions from greater exposures of <product>.
• Loss of therapeutic effect of <product> and possible development of resistance. See Table in • Keppra may cause somnolence and fatigue. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on Keppra to gauge whether it adversely affects their ability to drive or operate machinery.
• Asthenia • Somnolence and asthenia occurred most frequently within the first 4 weeks of treatment. In general, the incidences of somnolence and fatigue in the pediatric partial onset seizure studies and in pediatric and adult myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult partial onset seizure studies. Hematologic Abnormalities
• Keppra can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in red blood cell (RBC) counts, hemoglobin, and hematocrit, and increases in eosinophil counts. Decreased white blood cell (WBC) and neutrophil counts also occurred in clinical trials. Cases of agranulocytosis have been reported in the postmarketing setting. Increase in Blood Pressure
• Monitor patients 1 month to <4 years of age for increases in diastolic blood pressure. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm284241.htm (CONT.) (continued) 
